**

Overview

CAR‑T cell therapy (chimeric antigen receptor T‑cell therapy) harnesses the body’s adaptive immune system by genetically modifying a patient’s T cells to express synthetic receptors that bind a specific tumor antigen. These chimeric antigen receptors combine an extracellular antigen‑binding domain—usually derived from a monoclonal antibody’s single‑chain variable fragment (scFv)—with intracellular signaling motifs that trigger full T‑cell activation, proliferation, and cytotoxicity. After extraction, the T cells are transduced with a viral vector carrying the CAR construct, expanded in a laboratory, and then infused back into the patient, where they seek out and kill cancer cells expressing the target antigen.

Clinically, CAR‑T cells have shown remarkable efficacy against certain hematologic malignancies, especially B‑cell acute lymphoblastic leukemia (B‑ALL) and diffuse large B‑cell lymphoma (DLBCL). Response rates in heavily pre‑treated patients can exceed 80 %, with many achieving durable remissions. However, the therapy is associated with unique toxicities—most notably cytokine release syndrome (CRS) and immune effector cell‑associated neurotoxicity syndrome (ICANS). Management of these adverse events requires specialized monitoring and often intensive‑care support. Patients considering CAR‑T should discuss eligibility, potential benefits, and risks with an oncologist or hematologist experienced in cellular therapies.

History/Background

The concept of redirecting T cells with synthetic receptors emerged in the late 1980s, when researchers first fused antibody‑derived binding domains to T‑cell signaling components. Early “first‑generation” CARs contained only the CD3ζ signaling domain and produced modest activation. The breakthrough came in 1998 with the addition of a costimulatory domain (CD28 or 4‑1BB), creating “second‑generation” CARs that achieved robust expansion and persistence in vivo.

The first human trial of a CAR‑T product targeting CD19—a surface protein on B‑cells—was conducted in 2010 at the University of Pennsylvania. By 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Kymriah (tisagenlecleucel) for pediatric and young adult B‑ALL, followed shortly by Yescarta (axicabtagene ciloleucel) for adult DLBCL. Since then, multiple CAR‑T products have received regulatory clearance worldwide, and research has expanded to solid tumors, autoimmune diseases, and infectious diseases.

Key Information

- Target antigens: CD19 (B‑cell malignancies), BCMA (multiple myeloma), CD22, and emerging targets such as GD2 (neuroblastoma) and mesothelin (solid tumors). - CAR architecture: Extracellular scFv → hinge region → transmembrane domain → intracellular signaling (CD3ζ) plus one or two costimulatory domains (CD28, 4‑1BB, or OX40). - Manufacturing timeline: Leukapheresis → gene transfer (lentiviral or retroviral vectors) → ex‑vivo expansion (≈2‑3 weeks) → lymphodepleting chemotherapy → CAR‑T infusion. - Efficacy: In pivotal trials, overall response rates (ORR) of 81 % for Kymriah in B‑ALL and 82 % for Yescarta in DLBCL, with complete remission rates of 59 % and 54 % respectively. - Safety profile: CRS occurs in 60‑90 % of patients, ranging from mild fever to life‑threatening organ dysfunction; IL‑6 blockade (tocilizumab) and corticosteroids are mainstays of treatment. ICANS manifests as confusion, seizures, or cerebral edema; early neurologic assessment is critical. - Regulatory status: FDA‑approved products (as of 2024) include tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel. - Future directions: “Armored” CARs that secrete cytokines, universal allogeneic CAR‑T cells from healthy donors, and dual‑targeting CARs to overcome antigen escape.

Important: Anyone experiencing fever, low blood pressure, difficulty breathing, or neurologic changes after CAR‑T infusion should seek immediate medical attention, as these may signal severe CRS or ICANS.

Significance

CAR‑T cell therapy represents a paradigm shift from conventional chemotherapy and radiation to a living drug that can adapt, proliferate, and persist within the patient. Its success has validated the broader field of cellular immunotherapy, inspiring rapid investment in gene‑edited immune cells, bispecific antibodies, and vaccine‑based approaches. Economically, CAR‑T products are among the most expensive cancer treatments, prompting discussions about cost‑effectiveness, access, and health‑system sustainability. Ethically, the technology raises questions about manufacturing scalability, equitable distribution, and long‑term surveillance for late toxicities. Clinically, the ability to achieve deep, durable remissions in otherwise refractory cancers offers hope to patients and underscores the importance of multidisciplinary care teams that include oncologists, immunologists, critical‑care specialists, and pharmacists. As research expands into solid tumors and non‑oncologic indications, CAR‑T may become a versatile platform for precision medicine across a spectrum of diseases.

INFOBOX:
- Name: Chimeric Antigen Receptor T‑cell Therapy
- Type: Personalized cellular immunotherapy
- Date: First FDA approval – 2017 (Kymriah)
- Location: United States (global implementation)
- Known For: Transformative treatment of B‑cell malignancies with high remission rates

TAGS: CAR‑T, immunotherapy, hematologic malignancy, cytokine release syndrome, CD19, gene therapy, personalized medicine, oncology